Sanofi India Ltd Q4FY16
Standalone Results Q4FY16: (Rs. in crore)
|EBITDA Margin (%)||18.1|||
|Net Profit (adjusted)||50.50||[3.8]|
Sanofi India's Q4FY16 standalone results for the quarter registered a miss versus consensus estimates. Revenue for the quarter came in 6.3% lower than the estimated figure of Rs. 632 crore. And net profit for the quarter came in 40.1% lower than the estimated figure of Rs. 84.3 crore.
Sanofi India's standalone revenue for the quarter came in at Rs. 592 crore, registering 4.1% yoy increase.
EBITDA for the quarter fell 5% yoy to Rs. 107.3 crore with a corresponding margin contraction of 172 bps. EBITDA margin for the quarter stood at 18.1%. This was driven by increase in other expenses 28.5% yoy to Rs. 138.8 crore.
PAT for the quarter came in at Rs. 50.5 crore, yoy decline of 3.8%.
Sanofi India Ltd is currently trading at Rs. 4180, up by 41.35 points or 1% from its previous closing of Rs. 4138.65 on the BSE.
The scrip opened at Rs. 4165 and has touched a high and low of Rs. 4189 and Rs. 4132.05 respectively. So far 2016(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.
- Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
- Now Save Rs.3150 on your Demat Account ...Click here
- Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
- Get the most detailed result analysis on the web - Real Fast!
- Actionable & Award-Winning Research on 500 Listed Indian Companies.